Parameters evaluated
- Glucose fluxes
- Glucose turnover (= hepatic glucose production)
- Whole-body glycolysis rate
- Whole-body glycogen synthesis
- Glycemia
- Glucose clearance rate
State-of-the-art technique for investigating and quantifying the effect of your compound on whole-body glucose metabolism in a context of type 2 diabetes.
Glucose turnover using RADIOLABELED TRACERS is invaluable for assessing whole body GLUCOSE METABOLISM in vivo.
Key benefits
- Sensitivity (15%) sufficient to detect a statistically significant impact of your compound on glucose metabolism: a lack of significant results in blood glucose assays does not imply your drug compound doesn't improve glucose turnover.
- Essential and robust data for your records: isotopic glucose enrichment provides unique insights into whole-body glucose metabolism (glucose turnover, glycolysis and glycogen synthesis).
Species
- Rat
- Mouse
Add-on studies
- Individual tissue glucose uptake assay to identify specific tissues targeted by your compound, and to identify unexpected adverse effects or additional tissue-specific benefits.
- Euglycemic hyperinsulinemic clamp + 3H-glucose in the insulin-stimulated state to profile your compound's efficacy on Insulin sensitivity
- FFA turnover in basal conditions to complete your compound's lipid profiling.
Scientific publications
- Andreelli F et al, Endocrinology 147: 2432-41, 2006
- Burcelin R et al, Diabetes 49: 1635-42, 2000
- Burcelin R et al, Diabetes 48: 16264-9, 1999
